GlassScriptPhysician profile
Cassidy Inman
NPI 1205634367
$522.96
in general payments reported to CMS, 2019-2025
14 companies · $523 in 2025
The $523 reported for 2025 was more than what 84% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $68.95 | 2025 | Zurzuvae |
| Organon LLC | $67.70 | 2025 | Nexplanon |
| Novo Nordisk INC | $62.86 | 2025 | Ozempic, Wegovy |
| Millicent US INC | $55.56 | 2025 | Femlyv |
| Exeltis, USA INC. | $36.59 | 2025 | Slynd |
| Viiv Healthcare Company | $33.56 | 2025 | Apretude |
| Astellas Pharma US INC | $33.31 | 2025 | Veozah |
| Mayne Pharma Commercial LLC | $29.75 | 2025 | |
| Sanofi-Aventis U.S. LLC | $28.46 | 2025 | |
| Hologic Sales and Service, LLC | $27.59 | 2025 | Novasure |
| Abbvie INC. | $25.06 | 2025 | |
| Lilly USA, LLC | $19.38 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $17.57 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $16.62 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Inman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.